Abstract:Therapeutic Advances in Drug Safety, Volume 14, Issue , January-December 2023. Purpose:Unpredictable drug efficacy and safety of combined antiepileptic therapy is a major challenge during pharmacotherapy decisions in everyday clinical practice. The aim of this study was to describe the pharmacokinetics of valproic acid (VA), lamotrigine (LTG), and levetiracetam (LEV) in a pediatric population using nonlinear mixed-effect modeling, while machine learning (ML) algorithms were applied to identify any relationships among the plasma levels of the three medications and patients' characteristics, as well as to develop a predictive model for epileptic seizures.Methods:The study included 71 pediatric patients of both genders, aged 2–18 years, on combined antiepileptic therapy. Population pharmacokinetic (PopPK) models were developed separately for VA, LTG, and LEV. Based on the estimated pharmacokinetic parameters and the patients' characteristics, three ML approaches were applied (principal component analysis, factor analysis of mixed data, and random forest). PopPK models and ML models were developed, allowing for greater insight into the treatment of children on antiepileptic treatment.Results:Results from the PopPK model showed that the kinetics of LEV, LTG, and VA were best described by a one compartment model with first-order absorption and elimination kinetics. Reliance on random forest model is a compelling vision that shows high prediction ability for all cases. The main factor that can affect antiepileptic activity is antiepileptic drug levels, followed by body weight, while gender is irrelevant. According to our study, children's age is positively associated with LTG levels, negatively with LEV and without the influence of VA.Conclusion:The application of PopPK and ML models may be useful to improve epilepsy management in vulnerable pediatric population during the period of growth and development.Plain language summaryPharmacokinetics and machine learning in epilepsy Nowadays, combined antiepileptic therapy is the best option for a number of pediatric patients. Furthermore, there are no standard procedures in the therapy management of this complex treatment. Besides therapeutic monitoring, the population pharmacokinetic (PopPK) approach and machine learning (ML) are useful sources of information regarding the optimization of therapy. The aim of this study was to describe the pharmacokinetics of valproic acid (VA), lamotrigine (LTG), and levetiracetam (LEV) in a pediatric population using nonlinear mixed-effect modeling, while ML algorithms were applied to identify any relationships among the plasma levels of the three medications and patients' characteristics. The study included 71 pediatric patients of both genders, aged 2–18 years, on combined antiepileptic therapy. Population pharmacokinetic (PopPK) models were developed separately for VA, LTG, and LEV. Based on the estimated pharmacokinetic parameters and the patients' characteristics, three ML approaches were applied (principal component analysis, factor analysis of mixed data, and random forest). According to our study, children's age is positively associated with LTG levels, negatively with LEV and without influence from VA. However, the gender of patients has no influence on drug plasma concentration. Findings demonstrated that the application of PopPK and ML models may be useful to improve epilepsy management in vulnerable pediatric population during the period of growth and development.

A patient-centered equilibrium strategy for selecting anti-epileptic drugs in juvenile myoclonic epilepsy management

The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time?

A computational clinical decision-supporting system to suggest effective anti-epileptic drugs for pediatric epilepsy patients based on deep learning models using patient's medical history

Joint use of population pharmacokinetics and machine learning for optimizing antiepileptic treatment in pediatric population

Optimizing epilepsy treatment in children, adults and elderly: clinical perspectives

Medical management of epileptic seizures: challenges and solutions

Response to Antiseizure Medications in Epileptic Patients with Malformation of Cortical Development

Antiepileptic drugs: a consideration of clinical and biochemical outcome in patients with epilepsy

Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis

Anti-seizure Medications: Challenges and Opportunities

New anti-epileptic drugs

Prediction of antiepileptic drug treatment outcomes using machine learning

Comparing the Efficacy of Anti-Seizure Medications Using Matched Cohorts on a Large Insurance Claims Database

Models for predicting treatment efficacy of antiepileptic drugs and prognosis of treatment withdrawal in epilepsy patients

Machine learning models for predicting treatment response in infantile epilepsies

Lamotrigine vs levetiracetam in female patients of childbearing age with juvenile absence epilepsy: A Bayesian reanalysis

Evaluation of drug safety in pediatric epileptic patients: A prospective interventional study with clinical pharmacist intervention at a tertiary care teaching hospital

Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations

Anti-Seizure Medication Treatment of Benign Childhood Epilepsy with Centrotemporal Spikes: A Systematic Review and Meta-analysis

Pharmacokinetic considerations for anti-epileptic drugs in children

Épilexie: A digital therapeutic approach for treating intractable epilepsy via Amenable Neurostimulation